NUCLEOSIDES AND NUCLEOTIDES .107. 2-(CYCLOALKYLALKYNYL)ADENOSINES - ADENOSINE A2-RECEPTOR AGONISTS WITH POTENT ANTIHYPERTENSIVE EFFECTS

被引:44
作者
ABIRU, T [1 ]
MIYASHITA, T [1 ]
WATANABE, Y [1 ]
YAMAGUCHI, T [1 ]
MACHIDA, H [1 ]
MATSUDA, A [1 ]
机构
[1] HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN
关键词
D O I
10.1021/jm00090a017
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Adenosine receptor-binding profiles in rat brain tissues and antihypertensive effects in spontaneously hypertensive rats (SHR) of a series of 2-(cycloalkylalkynyl)adenosines (2-CAAs) and their congeners are described. The structure-activity relationship of this series of compounds is discussed, focusing on the length of the alkynyl side chain and bulkiness of the terminal cycloalkyl substituents in terms of binding activity and cardiovascular effects. All the 2-CAAs had a preferential affinity for A2 receptors. Of these derivatives, 2-(3-cyclopentyl-1-propyn-1-yl)adenosine (10b) exhibited the most selective affinity for A2 receptors (K(i) ratio: A1/A2 = 70) on the basis of receptor binding. In the C-2 binding region of adenosine, compounds often have potent and/or selective A2 activity from introduction of an acetylenic group at the C-2 position followed by one methylene residue further followed by a hydrophobic substituent such as a cycloalkyl ring at the terminal position of the alkynyl side chain. Intravenous injection of 10b up to 100-mu-g/kg had a potent hypotensive effect without a marked decrease in heart rate in anesthetized SHR. Compounds 10j-s, with a hydroxyl group in the C-3" position of the alkynyl side chain, had a potent affinity for both A1 and A2 receptors, but they were not highly selective for A2 receptors. These compounds caused a marked bradycardia upon intravenous administration in anesthetized SHR. Oral administration of 10b (0.1-1 mg/kg) had a potent and long-lasting antihypertensive effect in conscious SHR.
引用
收藏
页码:2253 / 2260
页数:8
相关论文
共 18 条
  • [1] THE ANTIHYPERTENSIVE EFFECT OF 2-ALKYNYLADENOSINES AND THEIR SELECTIVE AFFINITY FOR ADENOSINE A2-RECEPTORS
    ABIRU, T
    YAMAGUCHI, T
    WATANABE, Y
    KOGI, K
    AIHARA, K
    MATSUDA, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 196 (01) : 69 - 76
  • [2] N6-[2-(3,5-DIMETHOXYPHENYL)-2-(2-METHYLPHENYL)ETHYL]ADENOSINE AND ITS URONAMIDE DERIVATIVES - NOVEL ADENOSINE AGONISTS WITH BOTH HIGH-AFFINITY AND HIGH SELECTIVITY FOR THE ADENOSINE A2-RECEPTOR
    BRIDGES, AJ
    BRUNS, RF
    ORTWINE, DF
    PRIEBE, SR
    SZOTEK, DL
    TRIVEDI, BK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (07) : 1282 - 1285
  • [3] ADENOSINE RECEPTORS IN BRAIN MEMBRANES - BINDING OF N6-CYCLOHEXYL[H-3]ADENOSINE AND 1,3-DIETHYL-8-[H-3]PHENYLXANTHINE
    BRUNS, RF
    DALY, JW
    SNYDER, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (09): : 5547 - 5551
  • [4] BRUNS RF, 1986, MOL PHARMACOL, V29, P331
  • [5] DALY JW, 1987, CARDIAC ELECTROPHYSI, P41
  • [6] DIAGNOSTIC AND THERAPEUTIC USE OF ADENOSINE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIAS
    DIMARCO, JP
    SELLERS, TD
    LERMAN, BB
    GREENBERG, ML
    BERNE, RM
    BELARDINELLI, L
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (02) : 417 - 425
  • [7] HIGHLY SELECTIVE ADENOSINE-A2 RECEPTOR AGONISTS IN A SERIES OF N-ALKYLATED 2-AMINOADENOSINES
    FRANCIS, JE
    WEBB, RL
    GHAI, GR
    HUTCHISON, AJ
    MOSKAL, MA
    DEJESUS, R
    YOKOYAMA, R
    ROVINSKI, SL
    CONTARDO, N
    DOTSON, R
    BARCLAY, B
    STONE, GA
    JARVIS, MF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) : 2570 - 2579
  • [8] Haleen S J, 1985, Life Sci, V36, P127, DOI 10.1016/0024-3205(85)90091-8
  • [9] 2-(ARYLALKYLAMINO)ADENOSIN-5'-URONAMIDES - A NEW CLASS OF HIGHLY SELECTIVE ADENOSINE-A2 RECEPTOR LIGANDS
    HUTCHISON, AJ
    WILLIAMS, M
    DEJESUS, R
    YOKOYAMA, R
    OEI, HH
    GHAI, GR
    WEBB, RL
    ZOGANAS, HC
    STONE, GA
    JARVIS, MF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (07) : 1919 - 1924
  • [10] HUTCHISON AJ, 1989, J PHARMACOL EXP THER, V251, P47